TY - JOUR
T1 - Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer
AU - Robinson, Bruce
AU - Schlumberger, Martin
AU - Wirth, Lori J.
AU - Dutcus, Corina E.
AU - Song, James
AU - Taylor, Matthew H.
AU - Kim, Sung Bae
AU - Krzyzanowska, Monika K.
AU - Capdevila, Jaume
AU - Sherman, Steven I.
AU - Tahara, Makoto
N1 - Publisher Copyright:
Copyright © 2016 by the Endocrine Society.
PY - 2016/11
Y1 - 2016/11
N2 - Context: Lenvatinib improved the progression-free survival (PFS) and overall response rate of patients with radioiodine-refractory differentiated thyroid cancer vs placebo in the Phase 3 Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT). Objective: The objective of the study was to characterize tumor size changes with lenvatinib treatment. Design: SELECT was a phase 3, randomized, double-blind, multicenter study. Setting: In this clinical trial,tumorassessments of lenvatinib (n=261)andplacebo-treated (n=131) patients were performed by independent radiological review per Response Evaluation Criteria in Solid Tumors version, 1.1 at 8-week intervals. Patients: Patients with complete or partial response were defined as responders to lenvatinib (n= 169). Of the 92 nonresponders, 76 had at least one postbaseline tumor assessment and were included in this analysis. Interventions: Lenvatinib (24mgonce daily) or placebo in 28-day cycles until unacceptable toxicity, disease progression, or death. MainOutcomeMeasures: Thiswasanexploratory analysis of keyendpoints from SELECT, including PFS, overall response rate, and tumor reduction. Results: The medianmaximumpercentage change in tumor size was-42.9%for patients receiving lenvatinib (responders,-51.9%; nonresponders,-20.2%). Tumor size reduction was most pronounced at first assessment (median,-24.7%at 8wk after randomization); thereafter, the rate of change was slower but continuous (-1.3%per mo). In a multivariate model, percentage change in tumor size at the first assessment was a marginally significant positive predictor for PFS P= .06). Conclusions: The change in tumor size conferred by lenvatinib was characterized by two phases: an initial, rapid decline, followed by slower, continuous shrinkage. (J Clin Endocrinol Metab 101: 4103-4109, 2016).
AB - Context: Lenvatinib improved the progression-free survival (PFS) and overall response rate of patients with radioiodine-refractory differentiated thyroid cancer vs placebo in the Phase 3 Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT). Objective: The objective of the study was to characterize tumor size changes with lenvatinib treatment. Design: SELECT was a phase 3, randomized, double-blind, multicenter study. Setting: In this clinical trial,tumorassessments of lenvatinib (n=261)andplacebo-treated (n=131) patients were performed by independent radiological review per Response Evaluation Criteria in Solid Tumors version, 1.1 at 8-week intervals. Patients: Patients with complete or partial response were defined as responders to lenvatinib (n= 169). Of the 92 nonresponders, 76 had at least one postbaseline tumor assessment and were included in this analysis. Interventions: Lenvatinib (24mgonce daily) or placebo in 28-day cycles until unacceptable toxicity, disease progression, or death. MainOutcomeMeasures: Thiswasanexploratory analysis of keyendpoints from SELECT, including PFS, overall response rate, and tumor reduction. Results: The medianmaximumpercentage change in tumor size was-42.9%for patients receiving lenvatinib (responders,-51.9%; nonresponders,-20.2%). Tumor size reduction was most pronounced at first assessment (median,-24.7%at 8wk after randomization); thereafter, the rate of change was slower but continuous (-1.3%per mo). In a multivariate model, percentage change in tumor size at the first assessment was a marginally significant positive predictor for PFS P= .06). Conclusions: The change in tumor size conferred by lenvatinib was characterized by two phases: an initial, rapid decline, followed by slower, continuous shrinkage. (J Clin Endocrinol Metab 101: 4103-4109, 2016).
UR - http://www.scopus.com/inward/record.url?scp=84994853483&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84994853483&partnerID=8YFLogxK
U2 - 10.1210/jc.2015-3989
DO - 10.1210/jc.2015-3989
M3 - Article
C2 - 27548104
AN - SCOPUS:84994853483
SN - 0021-972X
VL - 101
SP - 4103
EP - 4109
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 11
ER -